Teva R&D Day: First-in-Class Bets on Tourette, Celiac and IBD

Teva took over the Ziegfeld Ballroom in New York on November 11, 2026, for the first research and development day in its forty years as a publicly traded company. The company rolled out more than ten drug programs, seven of them in late-stage development, with combined non-risk-adjusted peak sales projections exceeding $10 billion, according to Teva's investor materials. Three candidates got the spotlight for one reason: each goes after a biological pathway that no approved therapy currently touches. The backdrop is a company that spent a decade absorbing a generic price-fixing scandal, restructuring billions in debt, and watching its shares shed nearly 90 percent of their peak value.

First up is ecopipam, a selective D1 and D5 dopamine receptor antagonist for Tourette syndrome in pediatric patients. Every approved Tourette drug — haloperidol, pimozide, fluphenazine and their successors — works by blocking D2 receptors, and the side effects in children are well documented: sedation, weight gain, metabolic disruption and extrapyramidal symptoms. Teva bought Emalex Biosciences in June 2026 for a disclosed range of roughly $700 million to $900 million, landing the drug in near-NDA-ready shape. The pivotal Phase 2b trial ran 153 pediatric participants across 68 sites and showed a 69.8% reduction in Total Tic Score at eight weeks, holding through an 18-month open-label extension. The Phase 3 D1AMOND trial, published in JAMA Neurology in July 2026, enrolled 216 children at 77 sites in a randomized withdrawal design with time to relapse as the primary endpoint. The FDA accepted the new drug application on August 19, 2026, with Priority Review and Orphan Drug Designation; the PDUFA target date lands in late Q1 2027. CDC estimates put Tourette syndrome at about 3 per 1,000 school-age children in the US.

Second is TEV-'408, a fully human anti-IL-15 monoclonal antibody aimed at celiac disease and vitiligo through the same upstream target: interleukin-15, which is chronically overexpressed in both. In celiac patients with HLA-DQ2 or HLA-DQ8 haplotypes, IL-15 drives cytotoxic intraepithelial lymphocytes to attack the intestinal lining even without gluten, the mechanism behind refractory disease; ACG guidelines confirm no pharmacological treatment is approved and the gluten-free diet fails a meaningful slice of patients. In vitiligo, IL-15 sustains CD8-positive tissue-resident memory T cells in the epidermis that destroy melanocytes. The Phase 2a celiac trial, with results announced in September 2026, met its primary endpoint by cutting intraepithelial lymphocyte density with an acceptable safety profile. Phase 2b trials in both diseases are planned for 2027, and Royalty Pharma committed up to $500 million on January 11, 2026 — $75 million upfront, the rest tied to regulatory and commercial milestones. Incyte's ruxolitinib cream, sold as Opzelura, leads the vitiligo market, but its FDA label limits use to patches a patient can physically reach, leaving the face and scalp out.